Anti-wrinkle injections are the most widely offered injectable treatment in UK aesthetics. In our November 2026 dataset, 8,596 of the 20,269 venues we track list them on their treatment menu: 42% of the market.
Yet almost none of those venues tell you which product they inject.
What clinics say about toxin
| What the venue's website or menu says | Venues | Share |
|---|---|---|
| Names a specific toxin brand | 547 | 6% |
| Uses "Botox" as a catch-all, no other brand | 3,075 | 36% |
| No toxin brand or term at all | 4,974 | 58% |
| Total offering anti-wrinkle injections | 8,596 | 100% |
That is 3,075 venues using one manufacturer's brand name as a generic term for the whole category, against 547 that name any specific product.
Among the 547 that do, Azzalure is named most often (293 venues), followed by Bocouture (161), Relfydess (143), Alluzience (141) and Dysport (67). Nuceiva (18) and Letybo (15) barely register. 193 venues name more than one toxin.
Why toxin is different
The silence isn't an accident. Botulinum toxin is a prescription-only medicine, and the UK advertising code (CAP Code rule 12.2) bans advertising prescription-only medicines to the public. The Advertising Standards Authority's guidance is explicit that this covers product names such as Azzalure, Bocouture and Dysport, as well as logos and price lists. Clinics are expected to promote consultations for "lines and wrinkles", not named products.
Compare that with treatments regulated as medical devices, which can be promoted by name:
| Category | Venues offering it | Venues naming a brand | Share naming a brand |
|---|---|---|---|
| Skin boosters | 7,113 | 4,954 | 70% |
| Dermal fillers | 7,943 | 1,480 | 19% |
| Anti-wrinkle injections (toxin) | 8,596 | 547 | 6% |
Skin-booster brands are named eleven times as often as toxin brands.
What this means for toxin brands
The visible market is not a sample of the market. The 6% of venues that name a toxin are a small and unusual group, so brand shares calculated from them will mislead. Naming rates also vary by region, from 4.8% of toxin venues in London to 9.2% in the South West. London, the largest toxin market at 1,935 venues, is the least visible.
Website monitoring alone won't find your accounts. For more than nine in ten toxin venues, there is no public signal of which product they use. A brand that wants to know where it is used, and where it isn't, has to start from its own account list.
The useful question changes. Instead of "who mentions us?", ask "which of the 8,596 venues offering toxin are we already selling to, and which aren't we?" That needs a complete, maintained list of venues to match your accounts against. It should also carry the signals that do exist publicly: treatment menus, prices, practitioner type and ownership group.
How KalliData helps
KalliData maintains a reference database of more than 20,000 UK aesthetic venues, built from clinic websites, published treatment menus, Google and Companies House. We can match your account list against it and show you the venues offering toxin that you don't reach today.
Ask us for a free gap report, or a free sample dataset for an area of your choice, at kallidata.co.uk.